Search for: "Abbvie Biotechnology, Ltd."
Results 1 - 20
of 28
Sort by Relevance
|
Sort by Date
22 Jun 2020, 9:46 pm
District Court Judge for the Northern District of Illinois, dismissed (without prejudice) a class action lawsuit against AbbVie and AbbVie Biotechnology Ltd. by consumer groups, drug wholesalers, and unions (including the City of Baltimore, Miami Police Department insurance trust fund, and a Minnesota-based employee welfare benefits plan for workers in the pipe trade industries), alleging antitrust violations under Sections 1 and 2 of the Sherman Antitrust Act, as… [read post]
7 Apr 2020, 9:01 pm
AbbVie Biotechnology Ltd., IPR2018-00156, Paper 11 (June 5, 2018) (informative as to section III.C.1) (here) This decision determines that the Petitioner made a sufficient showing for purposes of institution that a drug package insert was publicly available, where the record included a screenshot of an archived FDA webpage from the Internet Archive and testimony from a medical doctor describing the use and accessibility of information on the FDA’s webpage. [read post]
22 Feb 2019, 3:48 am
AbbVie Biotechnology Ltd., Opposition No. 91238564 (January 24, 2019) [not precedential] (Opinion by Judge Lorelei Ritchie).Strength of Opposer's Mark: Applicant AbbVie contended that the letter sequence "RIZ" is entitled to a narrow scope of protection because the term is in common use in the pharmaceutical industry. [read post]
29 Jun 2018, 3:08 am
Brian Corderyby Craig Lumb After a decade-long hiatus, so-called Arrow declarations are now firmly back in fashion after the Court of Appeal’s judgment last year in Fujifilm Kyowa Kirin Biologics Co, Ltd v Abbvie Biotechnology Ltd & Anor [2017] EWCA Civ 1. [read post]
5 Feb 2018, 11:16 am
., and AbbVie Biotechnology Ltd. [read post]
4 Sep 2017, 8:49 pm
By Adrian M Trioli* & Noelene Treloar** -- The Australian Full Federal Court's recent decision in Commissioner of Patents v AbbVie Biotechnology Ltd [2017] FCAFC 129 confirms that an extension of patent term for pharmaceutical substances does not extend to Swiss type claims. [read post]
31 Aug 2017, 4:54 pm
A Full Court of the Federal Court has confirmed that patents containing “Swiss-style” claims are outside the scope of the Australian patent term extension regime in its recent judgment of Commissioner of Patents v AbbVie Biotechnology Ltd [2017] FCAFC 129. [read post]
31 Aug 2017, 4:54 pm
A Full Court of the Federal Court has confirmed that patents containing “Swiss-style” claims are outside the scope of the Australian patent term extension regime in its recent judgment of Commissioner of Patents v AbbVie Biotechnology Ltd [2017] FCAFC 129. [read post]
31 Aug 2017, 4:54 pm
A Full Court of the Federal Court has confirmed that patents containing “Swiss-style” claims are outside the scope of the Australian patent term extension regime in its recent judgment of Commissioner of Patents v AbbVie Biotechnology Ltd [2017] FCAFC 129. [read post]
31 Aug 2017, 4:54 pm
A Full Court of the Federal Court has confirmed that patents containing “Swiss-style” claims are outside the scope of the Australian patent term extension regime in its recent judgment of Commissioner of Patents v AbbVie Biotechnology Ltd [2017] FCAFC 129. [read post]
18 Aug 2017, 2:04 am
A Full Bench of three judges of the Federal Court of Australia has overturned an earlier decision of the Administrative Appeals Tribunal, and has ruled that extensions of patent term are not available for second and subsequent medical uses of pharmaceutical substances that are produced by recombinant DNA technology: Commissioner of Patents v AbbVie Biotechnology Ltd [2017] FCAFC 129 (AbbVie). [read post]
30 Apr 2017, 4:30 am
Fujifilm v AbbVie: practice, procedure and policy analysisGuest Kat Eibhlin Vardy summarizes the Rapid Response event organized by AIPPI on the case Fujifilm Kyowa Kirin Biologics Company Limited v AbbVie Biotechnology Limited, [2017] EWHC 395 (Pat), from the perspective of patent and competition law.Overturning a trade mark opposition decision - Part 2 - SOULUXE - likelihood of confusionGuest Kat Rosie Burbidge recaps the case SoulCycle Inc v Matalan Ltd,… [read post]
13 Mar 2017, 3:12 am
., Ltd and Others v AbbVie Biotechnology Limited by summarising the latest timeline events.BREAKING: High Court grants declaration that products obvious/anticipated at claimed priority datesFollowing AmeriKat’s notice, Eibhlin Vardy timely analysed the High Court’s decision on 3 March that granted declarations to Fujifilm Kyowa Kirin Biologics and Samsung Bioepsis and Biogen Idec to the effect that their products lacked novelty or an inventive step at a… [read post]
10 Mar 2017, 6:50 am
Brian Corderyby Laura Von Hertzen On 3 March 2017, the English Patents Court (Henry Carr J) issued a decision (here) in the joined claims filed by Fujifilm Kyowa Biologics (FKB) and Samsung Bioepis/Biogen (S/B) against AbbVie Biotechnology Limited (AbbVie) for so-called Arrow declarations in relation to dosage regimes of adalimumab (sold by AbbVie under the brand name Humira) for the treatment of rheumatoid arthritis and psoriasis/psoriatic arthritis. [read post]
8 Mar 2017, 9:26 am
., Ltd and Others v AbbVie Biotechnology Limited by summarising the latest timeline events.BREAKING: High Court grants declaration that products obvious/anticipated at claimed priority datesFollowed AmeriKat’s notice, Eibhlin Vardy timely analyzes the High Court’s decision on 3 March that has granted declarations to Fujifilm Kyowa Kirin Biologics and Samsung Bioepsis and Biogen Idec to the effect that their products lacked novelty or an inventive step at a… [read post]
2 Mar 2017, 1:02 pm
., Ltd and Others v AbbVie Biotechnology Limited ("FKB 1") is being handed down at 10:30AM London time.As soon as we digest the decision, GuestKat Eihblin Vardy, will be back to let readers know whether, despite having survived various interim attempts by AbbVie to kill it, the Arrow declaration has finally hit the target for Fujifilm ("FKB") and Samsung Bioepis/Biogen who want to market their adalimumab biosimilar. [read post]
22 Jan 2017, 11:49 am
., Ltd v AbbVie Biotechnology Ltd & Anor [2017] EWCA Civ 1, which involves two appeals, both raising the question of whether a Court can grant a so called ‘Arrow declaration’, i.e. a declaration that “a product was old or obvious in patent law terms at a particular date”.Guest Post - China's Patent BoomYangjin Li shares a guest post analysing the reasons why the State Intellectual Property Office of China (SIPO) tops the World… [read post]
18 Jan 2017, 3:34 am
Qiao Yongzhong's book “Maintenance time and the industry development of patents -- empirical research with evidence from China”Biosimilars battle in clearing the way - Fujifilm v AbbVie continuesFull low down on the interim decision handed down by Mr Justice Carr on 29 December in the biosimilars battle of Fujifilm Kyowa Kirin Biologics Co., Ltd and Others v AbbVie Biotechnology Limited [2016] EWHC 3383 (Ch).15 fully-funded IP PhD positions are… [read post]
13 Jan 2017, 9:24 am
., Ltd v AbbVie Biotechnology Limited and Others [2017] EWCA Civ 1. [read post]
5 Jan 2017, 4:11 am
., Ltd and Others v AbbVie Biotechnology Limited [2016] EWHC 3383 (Ch). [read post]
